GSK Plc: Jemperli RUBY Phase III Trial Meets Primary Endpoint

LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) reported positive headline results from the planned interim analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli

Related Keywords

London ,City Of ,United Kingdom , ,More Such Health News ,Jemperli ,Ruby ,Hase ,Trial ,Meets ,Primary ,Ndpoint ,